Responding To Multi-morbidity And Social Disadvantage Through General Practice: Practical Approaches To Understanding Best Practice And Incorporating Patient Views
Funder
National Health and Medical Research Council
Funding Amount
$408,387.00
Summary
I am a General Practitioner researcher focused on the problems related to chronic illness and social disadvantage. People living in disadvantaged circumstances suffer more chronic illnesses and the burden from those illnesses is greater for them. GPs trying to meet the needs of those patients face greater challenges. My research will identify strategies for enhancing the care provided and the experiences of patients in General Practice when faced with these difficulties.
Secondary Stroke Prevention: Strategies To Narrow The Gap Between Evidence And Practice
Funder
National Health and Medical Research Council
Funding Amount
$411,803.00
Summary
People who have had a stroke are at increased risk of having another stroke. Secondary stroke prevention is a neglected area of post-stroke care and the uptake of research evidence is poor. Barriers to evidence integration can include problems with the evidence and difficulties at the health professional and/or consumer level. This research will seek to understand the barriers and develop strategies to reduce the gap between evidence and clinical practice in secondary stroke prevention.
Therapeutics For Repair And Regeneration Of The Cornea
Funder
National Health and Medical Research Council
Funding Amount
$166,087.00
Summary
Corneal disease is the commonest cause of irreversible blindness and of the 50 million people world-wide who are bilaterally blind, 10 million are blind from corneal involvement. This proposal will address corneal disease by 1. innovative translational research for corneal repair and regeneration; 2. developing evidence-based management guidelines for corneal disease, and 3. by optimising health service delivery.
An In Depth Analysis Of Clinical And Virological Outcomes Of 2 Strategies For The Antiretroviral Salvage Of First-line Regimen Virological Failure For HIV-1 Infection Tested In An Australian-led Randomised, International, Multi-centre Clinical Trial
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
The recently completed Australian-led SECOND-LINE trial is the first high quality study to provide reliable evidence for policy recommendations for the composition of anti-HIV drug cocktails after standard initial treatment has failed. This award will support the researcher in further refining our understanding of how to manage second-line therapy including proposals to test the use of low-cost technologies for application in resource-limited settings where the majority of people with HIV live.
Monoclonal antibodies, such as the breast cancer therapeutic Herceptin, have revolutionised the treatment of cancer and inflammatory conditions. Will over $30 billion sales in 2011, they have also spawned a growing biotech industry. We have a generated a highly specific monoclonal antibody, which has shown efficacy in models of disease. This project will further advance and develop this monoclonal, allowing us to initiate clinical studies in patients.
Afinity Maturation And Development Of An Anti-inflammatory Monoclonal Antibody
Funder
National Health and Medical Research Council
Funding Amount
$387,489.00
Summary
Antibodies are a relatively new class of drugs that directly target molecular mechanisms of disease. Antibody therapies, such as the breast cancer drug Herceptin, have significantly increased our arsenal of effective therapeutics. In collaboration with G2 Therapies, we will use cutting-edge genetic engineering technology to produce fully human antibodies for the treatment of inflammatory diseases, such as rheumatoid arthritis.
Tumour-on-a-chip Models For Ex-vivo Profiling Of Immune Checkpoint Blockades
Funder
National Health and Medical Research Council
Funding Amount
$431,000.00
Summary
The overall goal of this project is to build novel 3D biochips to culture primary human tumors with their immune cells, and to investigate patient specific responses to immune checkpoint blockade ex-vivo. Since there are currently no validated methodologies to study immunotherapy response in patient-derived cancer specimens, this proposal has the potential to provide a state-of-the art technology for the ‘personalization’ of immunotherapy.